MaxCyte Announces Proposed Cancellation of AIM Listing
Why we think this is good
The RNS announcement outlines MaxCyte's intention to cancel the admission of its common stock to trading on the AIM market of the London Stock Exchange. The company will retain its U.S. listing on Nasdaq and believes the delisting will enhance the liquidity of trading in its shares and reduce duplicative costs. The proposed delisting is subject to stockholder approval, and the company will continue to engage with its UK-based shareholders following the delisting. Overall, the news appears positive for the company's operations and shareholder value, though the loss of the AIM listing may be seen as a negative by some investors.
Key Points
- MaxCyte plans to cancel the admission of its common stock to trading on the AIM market
- The company will retain its U.S. listing on the Nasdaq Global Select Market
- The Board believes the delisting will enhance liquidity and reduce duplicative costs
- The proposed delisting is subject to stockholder approval at the annual meeting
- If approved, the last day of trading on AIM is expected to be June 25, 2025
Summary
MaxCyte, Inc., a leading cell-engineering focused company, has announced its intention to cancel the admission of its common stock to trading on the AIM market of the London Stock Exchange. The company will retain its U.S. listing on the Nasdaq Global Select Market.
The Board believes that the delisting will enhance the liquidity of trading in the company's shares on Nasdaq and reduce duplicative costs associated with maintaining a dual listing. Following the delisting, MaxCyte will continue to engage with its UK-based shareholders.
The proposed delisting is subject to stockholder approval, which will be sought at the company's annual meeting of stockholders. If approved, the last day of trading on AIM is expected to be June 25, 2025, with the cancellation of admission to trading taking effect on June 26, 2025.